Letter to Shareholders from Sean Carrick
Dear Shareholder, The past eighteen months have been a challenging time for Nascent Biotech. After successfully completing Phase I establishing safety at multiple ascending cohorts and showing [...]
Message From Senior Management
601 21st Street, Suite 300 Vero Beach, FL 32960 February 11, 2025 Dear Shareholder: Our fiscal year will end March 31, 2025, and this year has proven to be challenging, yet productive. We [...]
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”), a clinical-stage biotechnology [...]
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
Analysts suggest Nascent Value at $0.60 to $2.84 per share NORTH PALM BEACH, FL / ACCESSWIRE / January 9, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, [...]
Marble Arch Research: What is Pritumumab and How it Works
CLICK HERE TO DOWNLOAD COMPLETE PDF
Nascent Biotech Regains Worldwide Rights for Pritumumab
NORTH PALM BEACH, FL / ACCESSWIRE / May 26, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]
NBIO Link Report for May 10, 2023
Wall Street PR Apple News StreetInsider.com QuoteMedia WallStreetPR Facebook LinkedIn
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]